CompletedNot Applicable

Neurodevelopment at 5.5 Years of Age in Children Who Received Infant Formula With Enriched Protein Fractions

China116 participantsStarted 2020-06-15

Plain-language summary

This is a follow-up study of a multi-center, double-blind, randomized, controlled, parallel-designed, prospective trial and is intended to evaluate neurodevelopment at 5.5 years of age and health outcomes through 5.5 years of age in participants who received one of two staged study formulas through one year of age.

Who can participate

Age range64 Months – 68 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participant who previously consumed study formula through one year of age in MJN Project 6027 * 5.5 years of age (i.e. when child turns 5 years and 6 months old ± 2 months) at Visit 1 * Signed informed consent obtained for child's participation in the study Exclusion Criteria: * No exclusion criteria

What they're measuring

Wechsler Preschool & Primary Scale of Intelligence™ (Fourth Edition; WPPSI™-IV)

Timeframe: At 5.5 years of age

Trial details

NCT IDNCT04442477

SponsorMead Johnson Nutrition

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2021-05-27

View on ClinicalTrials.gov More Cognitive Ability, General trials